A new method published in Nature Methods by researchers at the New York Genome Center (NYGC) and Weill Cornell Medicine (WCM) — including corresponding author Dan Landau, MD, PhD, NYGC Core Faculty Member and member of the Englander Institute for Precision Medicine and the Sandra and Edward Meyer Cancer Center at WCM — presents a significant advancement in cancer diagnostics: the use of low-cost whole-genome sequencing platforms to detect small traces of cancer DNA in blood.
Dr. Landau, along with lead author Alexandre Pellan Cheng, Associate Professor, École de technologie supérieure, Canada, recently spoke to The Analytical Scientist about the new method and its potential to transform everyday cancer diagnostics with a more cost-effective, minimally invasive approach.
Click here to read the full piece.
